Business
Premier Biomedical Announces Intended $6 Million Investment by Brazilian Joint Venture Partner, Auramedi, to Manufacture, Market and Distribute Premier’s New Technology Products
Premier Biomedical Announces Intended $6 Million Investment by Brazilian Joint Venture Partner, Auramedi, to Manufacture, Market and Distribute Premier’s New Technology Products.
About this update from Premier Biomedical Inc
[{"type":"text","content":"\n \n Premier Biomedical, Inc.(OTCQB:\"BIEI\") \n a biotech research company focused on discovering, developing, and \n commercializing medical treatments for a wide range of diseases in \n humans, including innovative therapies for breast cancer, as well as for \n fibromyalgia, neuropathy, atherosclerosis and muscular dystrophy \n confirmed today that its planned Brazilian joint venture partner, \n Auramedi Farmacêutica, Ltd., has announced its intention to invest up to \n BRL$25 Million (USD$ 6 Million) to establish facilities for the \n manufacture, distribution and sale of Premier Biomedical drugs and other \n treatments in Brazil and South America.\n \n \n A source inside Auramedi, familiar with the matter, has confirmed the \n intentions of the Brazilian company to develop the JV, and the \n possibility of accelerating the investment, once the JV partnership is \n consummated. “Auramedi’s master plan established that we would invest \n from 20 to 25 Million Brazilian Real over the next five years, to set up \n our facility. However, with the advent of the joint venture, this amount \n could be invested earlier, due to the confidence we have regarding the \n success potential of this endeavor.” the source said.\n \n \n Premier is working, with Auramedi's support, on investigations to apply \n Premier’s extracorporeal technology toward finding a cure for the Zika \n and Dengue viruses.\n \n \n William A. Hartman, President and CEO of Premier Biomedical stated, “We \n are extremely pleased with the progress and interest Auramedi has shown \n in the development and success of this Brazilian joint venture. Their \n top management has participated in regular meetings with Premier, and \n continues to do so. We are confident the remaining issues in \n establishing the JV will be resolved in short order.”\n \n \n Contact William Hartman at (724) 633-7033, [email protected].\n \n \n About Premier Biomedical, Inc.\n \n \n Premier \n Biomedical, Inc. (OTCQB: BIEI) \n is a research-based company that intends to discover and develop medical \n treatments for a wide range of diseases in humans. Premier has obtained, \n via license agreements, the technology behind three granted U.S. \n patents, multiple pending provisional patents, and a PCT Europe National \n Patent. Founded in 2010, Prem...